Planned Investment in Sligo Centre of Excellence secures 120 jobs
The economy in the North West has received a welcome boost with the confirmation by Elanco Animal Health of its long-term commitment to its recently acquired Animal Vaccine plant in Sligo. The announcement of ongoing investment and the commensurate opportunities this will create for the existing work force in Sligo coincided with today’s visit (Friday October 15th) by Minister for Agriculture Fisheries and Food , Mr. Brendan Smith T.D., to the Sligo facility. He was met by Dr Pat Glynn, Sligo Site Manager and Dr Stephen Chu, Elanco’s distinguished research fellow. The visit included a tour of the vaccine facility and a meeting with members of the Site Leadership Team.
Doctors Glynn and Chu stressed to Minister Smith the importance of innovative veterinary vaccines and Elanco’s intention to become a major player in the development and manufacture of such vaccines. Dr Chu added, “The EU is a strategically important region for Elanco investment and growth and our Sligo plant is critical to Elanco's vaccine business development in the region. The Sligo workforce has outstanding qualities and a depth of experience in vaccine manufacture and is dedicated to providing the best service to the animal health industry in Ireland and rest of EU for many years to come”.
Dr Chu noted that we live in a world where the relatively free movement of livestock is an everyday occurrence. The risk of disease spread, therefore, remains extremely high. Europe’s experience with Bluetongue virus and Ireland’s with Foot & Mouth over recent years is a case in point. The reality is that diseases do not respect borders.
He continued: “Elanco has also set up a new vaccine research and development (R&D) team incorporating some of the best talent in the business with excellent track records in vaccine innovation and registrations in the EU and other parts of the world. This team will provide full support to our Sligo plant in the areas of product innovation and new product introductions. Additionally this R&D team will seek opportunities to collaborate with partners in Ireland”.
Dr Chu concluded: “Elanco is committed to the long-term success of the Sligo plant and the growth of our vaccine business in the EU.”
Minister Brendan Smith highlighted the importance of the ongoing investment to the region: “The planned investment in this site will represent a welcome additional injection into the economy of the Sligo and the broader North West Region. It will also, I am sure, bring additional confidence for your 120 employees here that they can build their highly-specialised careers in a facility which, through new technology and up-skilling, will keep them at the cutting edge of animal vaccine production in international terms. From the Irish Government’s perspective, the high end, graduate jobs here fit very well into our vision for the Irish economy in the years ahead,” he explained
The Elanco vaccine facility in Sligo is an IDA supported initiative. Commenting on the company’s commitment to maintain the plant as a Centre of Excellence for vaccine manufacture, IDA’s Chief Executive, Barry O’Leary, highlighted the significance of this investment for the North West region.
“The planned investment in this facility secures the 120 jobs at Elanco’s plant in Sligo and strengthens its strategic importance within the parent company, Eli Lilly. Other Lilly investments in Ireland include its 100 person European Financial Services Centre announced in July and the €400m investment made at its Biopharmaceutical facility in Kinsale bringing total headcount in Lilly in Ireland to over 600. It demonstrates that Ireland continues to attract manufacturing activities from leading global companies and assists IDA Ireland to promote the North-West region for further Life Science investments.”
CONTACT: Alan Allister (Elanco +353 87 260 9625)
SLIGO – Republic of Ireland
CONTACT: Thomas McEvoy (IDA +353 87 742 6684)
DUBLIN – Republic of Ireland
Elanco is a global innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at www.elanco.com.
The EU is a strategically important region for Elanco investment and growth and our Sligo plant is critical to Elanco's vaccine business development in the region.Dr Stephen Chu, Elanco’s distinguished research fellow